Twist Bioscience and Ono Pharmaceutical enter agreement for discovery of novel antibodies
Betsy Goodfellow | August 31, 2023 | News story | Research and Development | Immunology, Ono Pharmaceutical, Twist Bioscience, antibodies, autoimmune diseases
Twist Bioscience has announced that it has entered a drug discovery agreement with Ono Pharmaceutical for the discovery and development of novel antibodies for the treatment of various autoimmune diseases.
Under the terms of this agreement, Twist is expected to use the Twist Biopharma Solutions Library of Libraries to conduct research activities in order to discovery novel antibodies against targets that will be identified by Ono. According to the company’s press release, the Library of Libraries is an “expansive collection of synthesised antibody libraries based on naturally occurring sequences that harness innovative structural and developability features to cover a wide range of drug targets.”
Twist will be granted research fees, success-based clinical and regulatory milestone payments and royalties on product sales, while Ono will evaluate new targets and generate discovery campaigns. Ono will then be responsible for the development, manufacturing and commercialisation of any resultant products.
Emily M Leproust, PhD, CEO and co-founder of Twist Bioscience, commented: “Ono has a strong and proven track record in developing antibody candidates in areas of need, including the development of the anti-PD-1 antibody Opdivo, which has had a tremendous impact for patients and researchers. This collaboration bringing together our antibody discovery expertise with Ono’s experience in drug development has the potential to lead to future breakthrough treatment options for patients with autoimmune diseases.”
Dr Toichi Takino, senior executive officer and executive director, Discovery and Research at Ono, added: “We are actively working to create biologics like antibodies in order to address unmet medical needs for a wide range of diseases including autoimmune diseases. We are very pleased to collaborate with Twist at this time in the area of autoimmune diseases and are confident that their expertise in antibody discovery and their impressive collection of diverse and highly specific antibody libraries will bring us potential functional antibodies. We believe that this new collaboration will enhance our biologics drug discovery efforts and bring innovative drugs for patients as soon as possible.”
Betsy Goodfellow
Related Content
Prism BioLab and Ono Pharmaceutical enter joint research and licensing agreement
Prism BioLab has announced that it has entered into a target-exclusive research and licensing agreement …
Kymera Therapeutics reports positive data in cancer drug trials
US clinical-stage biopharmaceutical company Kymera Therapeutics has shared new data regarding its oncology programmes KT-333 and …
Ground-breaking COVID antibody treatment proven to save lives
Results from Regeneron’s Recovery trial, investigating a potent monoclonal antibody combination treatment in hospitalised patients …
